Deracoxib-d4

Deracoxib-d4 (SC 046-d4; SC 59046--d4) is deuterium labeled Deracoxib. Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

1794780-24-7

SC 046-d4; SC 46-d4; SC 59046-d4

12352005

Apoptosis; COX; Isotope-Labeled Compounds

Apoptosis; Immunology/Inflammation; Others

COVID-19-immunoregulation

Cancer; Inflammation/Immunology; Neurological Disease

[2H]C1=C([2H])C(S(=O)(N)=O)=C([2H])C([2H])=C1N2C(C3=CC(F)=C(OC)C=C3)=CC(C(F)F)=N2

C17H10D4F3N3O3S

401.40

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Royals, S.R., et al., Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res, 2005. 66 (11) : p. 1961-7.|[3]Ustun Alkan, F., et al., The effects of piroxicam and deracoxib on canine mammary tumour cell line. ScientificWorldJournal, 2012. 2012: p. 976740.|[4]Bienhoff, S.E., et al., Efficacy and safety of deracoxib for control of postoperative pain and inflammation associated with soft tissue surgery in dogs. Vet Surg, 2012. 41 (3) : p. 336-44.|[5]McMillan, S.K., et al., Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc, 2011. 239 (8) : p. 1084-9.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W703540/

Isotope-Labeled Compounds

No Development Reported